ICMR, Pfizer to work on antimicrobial resistance

Published On 2018-02-03 05:15 GMT   |   Update On 2018-02-03 05:15 GMT

New Delhi: The Indian Council of Medical Research (ICMR) and Pfizer said they will set up a centre to address the growing threat of antimicrobial resistance in India.


The ‘Centre to Combat Antimicrobial Resistance’ in New Delhi will be set up as a part of the memorandum of understanding signed recently, they added.



The joint initiative will implement comprehensive interventions, ranging from antimicrobial resistance (AMR) stewardship programmes for nursing homes to scaling up of the ongoing AMR surveillance network and creating awareness around responsible use of antibiotics, the joint statement said.

Pfizer has provided an initial grant of Rs 6.97 crore for this initiative with a provision to scale up further as the program expands, it added.


“The Government of India recognizes the need for urgent action and hence is developing a national response mechanism to adeptly deal with the growing challenge of antimicrobial resistance,” Department of Health Research Secretary & ICMR Director General K Vijay Raghavan said.


Adopting a partnership approach with Pfizer, ICMR is engaging with relevant stakeholders to draw in diverse perspectives and support, he added.


Commenting on the development, Pfizer Ltd MD S Sridhar said: The pharmaceuticals industry must respond in full force to support the Government’s ambitious plan to combat antimicrobial resistance.”


“Pfizer recognizes the serious public health threat associated with anti-microbial resistance and we work closely with the governments and public health community to address the crisis of drug-resistant infection,” Regional President of APAC Pfizer Essential Health, Pierre Gaudreault said.


The Government of India views AMR as a key priority and in April 2017 finalized country’s National Action Plan on Antimicrobial Resistance (NAP-AMR), the statement said.

Article Source : PTI

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News